Sputum DNA test aims to outsmart Drug-Resistant TB

NCT ID NCT05007795

Not yet recruiting Diagnosis Sponsor: University of Cape Town Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial tests a new DNA test that reads drug resistance directly from sputum samples in people with multidrug-resistant tuberculosis (MDR-TB). The goal is to see if this test helps doctors prescribe at least five effective drugs within 14 days of diagnosis, compared to current slower methods. About 280 adults with rifampicin-resistant TB will take part. If it works, this approach could lead to more personalized and effective treatment for drug-resistant TB.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Targeted sequencing test (GenoScreen Deeplex assay)
What this could lead to: If successful, this test could help doctors choose the right drugs faster for people with drug-resistant TB, potentially improving cure rates.
What could go wrong: This is a small, early-stage proof-of-concept trial. The test may not be faster or more accurate than current methods, and results may not apply to all settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RIFAMPICIN-RESISTANT TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multidrug-resistant tuberculosis rifampicin-resistant tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS, MULTIDRUG-RESISTANT

Contacts and locations

Locations

University of Cape Town

Cape Town, Western Cape, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.